S-8510 phosphate (SB-737552 phosphate) (Synonyms: SB-737552 phosphate) |
| Catalog No.GC31121 |
Le S-8510 (phosphate) est un agoniste inverse des récepteurs des benzodiazépines (BDZ), avec Kis de 34,6 nM, 36,2 nM pour -GABA et +GABA respectivement.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 151466-23-8
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
S-8510 (phosphate) is an inverse Benzodiazepine (BDZ) receptor agonist, with Kis of 34.6 nM, 36.2 nM for -GABA and +GABA respectively.
S-8510 has a relatively high affinity to BDZ receptors. The ratio of Ki values for each ligand with and without GABA is defined as the GABA ratio, which is considered as a biochemical index for BDZ receptor ligands. The GABA ratio for S-8510 or CGS8216 is close to the value for flumazenil which is considered as an antagonist or a very weak agonist. S-8510 (10-7 M) enhances LTP and this enhancement is antagonized by BDZ receptor antagonist, flumazenil. Flumazenil itself does not atfect LTP or evokes responses prior to tetanic stimulation. S-8510 has no effect on the field evoked potential up to 10-5 M. However, S-8510 increases the amplitude of the population spike at a dose of 10-4 M, and this effect is completely antagonized by concomitant application of flumazenil (10-4 M) [1].
S-8510 or CGS8216 could cause lethal convulsion only in combination with more than 90 mg/kg of PTZ. The proconvulsant activity of S-8510 appears to be selective for PTZ-induced subconvulsive state. Scopolamine decreases the time spending in the area around the platform, indicating the amnesic action of scopolamine. S-8510 and CGS8216 reverses this scopolamine-induced amnesia. S-8510 improves the memory impairment induced by diazepam in the water maze and passive avoidance paradigms as well. S-8510 dose-dependently increases the ACh level up to 100 mg/kg. Both S-8510 and PTZ increases the extracellular level of NA in the hippocampus in a dose-dependent manner. Anxiogenic actions of S-8510, CGS8216 and FG7142 are examined in the water lick conflict paradigm of Wistar rats. S-8510 and CGS8216 fail to affect this behavioral paradigm up to 30 mg/kg. S-8510 significantly decreases the immobility time in the forced swimming test using ddY mice at 40 to 80 mg/kg in a dose-dependent manner. In the tetrabenazine-induced ptosis model, S-8510 significantly reduces the extent of ptosis induced by tetrabenazine at doses more than 10 mg/kg. Again, S-8510 reduces the extent of ptosis only by 39% even at the maximum dose, whereas imipramine exerts more pronounced effects (by about 80% at a dose of 20 mg/kg)[1].
[1]. Kawasaki K, et al. A novel benzodiazepine inverse agonist, S-8510, as a cognitive enhancer. Prog Neuropsychopharmacol Biol Psychiatry. 1996 Nov;20(8):1413-25.
Animal experiment: | Mice, Rats[1]Proconvulsant actions of S-8510 are examined in combiition with a subconvulsive dose of convulsant (PTZ or strychnine) or minimal electroconvulsive shock in ddY mice. Each convulsant is administrated, simultaneously with the inverse agonist, whereas minimal electroconvulsive shock is applied 5 min after intravenous injection of the inverse agonist. The proconvulsant test of S-8510 on PTZ (52, 62.5, 75 or 90 mg/kg s.c.) or strychnine (0.25 mg/kg, s.c.)-induced convulsion is made. ED50 values for producing clonic convulsion to death in 50% of ddY mice are calculated. Anxiogenic actions of each inverse agonist are examined in the punished water licking method in Wistar rats. Each inverse agonist is administered per OS 30 min before the test trial. Antiamnesic actions of inverse agonists are examined in the water maze paradigm. Wistar rats are given 4 trials every day for consecutive 4 days. On the 5 th day, each animal has the retention test for 60 s. Amnesia is produced by intraperitoneally injected scopolamine at a dose of 0.5 mg/kg. Scopolamine and each inverse agonist are given 15 min and 30 min before the retention trial, respectively[1]. |
References: [1]. Kawasaki K, et al. A novel benzodiazepine inverse agonist, S-8510, as a cognitive enhancer. Prog Neuropsychopharmacol Biol Psychiatry. 1996 Nov;20(8):1413-25. | |
| Cas No. | 151466-23-8 | SDF | |
| Synonymes | SB-737552 phosphate | ||
| Canonical SMILES | O=P(O)(O)O.C12=NC=C3C(NC(C4=NOC=C4)=N3)=C1COCC2 | ||
| Formula | C12H13N4O6P | M.Wt | 340.23 |
| Solubility | Soluble in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.9392 mL | 14.6959 mL | 29.3919 mL |
| 5 mM | 0.5878 mL | 2.9392 mL | 5.8784 mL |
| 10 mM | 0.2939 mL | 1.4696 mL | 2.9392 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 35 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *